

# Computational Design of an Unnatural Amino Acid Dependent Metalloprotein with Atomic Level Accuracy

Jeremy H. Mills,<sup>†</sup> Sagar D. Khare,<sup>†,#</sup> Jill M. Bolduc,<sup>‡</sup> Farhad Forouhar,<sup>§</sup> Vikram Khipple Mulligan,<sup>†</sup> Scott Lew,<sup>§</sup> Jayaraman Seetharaman,<sup>§</sup> Liang Tong,<sup>§</sup> Barry L. Stoddard,<sup>‡</sup> and David Baker<sup>\*,†,||,⊥</sup>

<sup>†</sup>Department of Biochemistry and <sup>⊥</sup>Biomolecular Structure and Design Program, University of Washington, Seattle, Washington, United States

<sup>‡</sup>Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States


<sup>§</sup>Department of Biological Sciences, Northeast Structural Genomics Consortium, Columbia University, New York, New York, United States

<sup>||</sup>Howard Hughes Medical Institute, University of Washington, Seattle, Washington, United States

## Supporting Information

**ABSTRACT:** Genetically encoded unnatural amino acids could facilitate the design of proteins and enzymes of novel function, but correctly specifying sites of incorporation and the identities and orientations of surrounding residues represents a formidable challenge. Computational design methods have been used to identify optimal locations for functional sites in proteins and design the surrounding residues but have not incorporated unnatural amino acids in this process. We extended the Rosetta design methodology to design metalloproteins in which the amino acid (2,2'-bipyridin-5yl)alanine (Bpy-Ala) is a primary ligand of a bound metal ion.

Following initial results that indicated the importance of buttressing the Bpy-Ala amino acid, we designed a buried metal binding site with octahedral coordination geometry consisting of Bpy-Ala, two protein-based metal ligands, and two metal-bound water molecules. Experimental characterization revealed a Bpy-Ala-mediated metalloprotein with the ability to bind divalent cations including  $\text{Co}^{2+}$ ,  $\text{Zn}^{2+}$ ,  $\text{Fe}^{2+}$ , and  $\text{Ni}^{2+}$ , with a  $K_d$  for  $\text{Zn}^{2+}$  of  $\sim 40$  pM. X-ray crystal structures of the designed protein bound to  $\text{Co}^{2+}$  and  $\text{Ni}^{2+}$  have RMSDs to the design model of 0.9 and 1.0 Å respectively over all atoms in the binding site.



## INTRODUCTION

Methods allowing site-specific incorporation of genetically encoded unnatural amino acids (UAAs) into proteins<sup>1</sup> offer great promise for the creation of biomolecules with novel function. Physical and chemical properties of proteins that emerged in biological systems only after eons of selective pressure can now be encoded in a single amino acid side chain.<sup>2</sup> Designing new functional sites with UAAs will require optimizing the chemical and structural environment around the UAA for the desired function. For example, a designed enzyme utilizing an UAA to provide a potent nucleophile or electrophile would also require appropriately positioned amino acids to correctly orient the UAA, to carry out additional catalytic roles (such as proton transfer) and to bind the substrate in an orientation suitable for catalysis. Computational protein design methods can, in principle, solve this problem by simultaneously positioning multiple residues, but such methods have focused thus far on design using only the 20 naturally occurring amino acids.


Metalloproteins carry out a diverse spectrum of important biological functions including oxygen transport, photosynthesis, respiration, nitrogen fixation, and water oxidation.<sup>3</sup> The ability to precisely design metal binding sites in proteins would in turn

facilitate the design of new enzyme catalysts as well as novel metal dependent protein folding or protein–protein interactions. Considerable work has aimed at designing novel metalloproteins,<sup>4–8</sup> but achieving atomic level accuracy has been challenging, as there are generally many alternative ways to form a metal binding site from flexible polar amino acid sidechains.<sup>9–11</sup> Two UAAs with the ability to bind metal have been added to the genetic code of *Escherichia coli* to date. Both (2,2'-bipyridin-5yl)alanine (Bpy-Ala)<sup>12</sup> and (8-hydroxyquinolin-3-yl)alanine (HQ-Ala)<sup>13</sup> have an inherent ability to bind diverse sets of metal ions with various affinities. From a computational protein design perspective, bidentate metal binding UAAs reduce the complexity of metal binding site design because of high inherent affinity for metal and by eliminating the need to make hydrogen bonds to unsatisfied donors or acceptors (as would be the case for the unliganded nitrogen in a His side chain contributing to a metal binding site).

Here, we describe the use of the Rosetta computational design methodology to engineer a metal binding site in a

Received: April 8, 2013

Published: August 7, 2013



**Figure 1.** Spectral and structural analysis of round 1 designs. (a) Absorbance spectra of designs CB\_02 (solid line) and CB\_12 (dashed line). The spectrum in the 425–650 nm range (inset) is consistent with a  $[\text{Fe}(\text{Bpy})_3]^{2+}$  complex. Spectra were normalized to an  $A_{280}$  of 1.0. (b) Superposition of CB\_02 design with the structure solved at 1.4 Å. The design is shown in gray, the structure in yellow, and the dopamine ligand in green sticks. The Bpy-Ala containing loop in the CB\_02 structure is colored red. No density corresponding to the Bpy-Ala side chain was observed in the structure; the position of incorporation in the flipped out loop is colored blue.

protein initially lacking that capacity utilizing a genetically encoded Bpy-Ala as the primary metal ligand. A first round of design provided insight into factors that must be considered when utilizing UAAs with strong intrinsic metal binding affinities in design. A second round of design resulted in the identification of a Bpy-Ala-mediated metal binding site in which an octahedral coordination sphere around the bound metal ion is formed by Bpy-Ala, natural amino acid side chains, and explicitly modeled bound water molecules. The designed protein binds a range of divalent cations, including  $\text{Zn}^{2+}$  (with a dissociation constant in the pM range),  $\text{Co}^{2+}$ ,  $\text{Ni}^{2+}$ , and  $\text{Fe}^{2+}$ , and the X-ray crystal structure is nearly identical to the design model.

## RESULTS

**Lessons from Initial Design Efforts.** We first set out to design an active site to catalyze oxidative ring-opening of catechol substrates. Four theoretical enzyme active sites (‘theozymes’, Supporting Information (SI) Figure 1) were constructed through analysis of a crystal structure of a small molecule complex of bipyridine (Bpy), iron, and 3,6-di-*tert*-butylcatechol from the Cambridge Structural Database (CSD entry ZAZHAJ). As in natural catechol dioxygenases, the iron atom in this small molecule structure is coordinated by the phenols of the catechol moiety. Components of the theozymes included Bpy-Ala, the catechol containing small molecule dopamine, and two additional ligands to the metal that were allowed to be tyrosine or histidine. RosettaMatch<sup>14</sup> was used to identify sets of backbone positions in naturally occurring protein scaffolds with geometries that allow recapitulation of the theozyme geometries. For each of these ‘matches’, RosettaDesign<sup>15</sup> was used to introduce additional interactions to stabilize the Bpy-Ala complex, and the resultant designs were filtered on how well the geometric constraints were satisfied by the design, whether or not the metal ligands were displaced during an attempt to repack designed side chains in the absence of the metal and dopamine ligand, and the orientation of the dopamine substrate within the active site. Genes encoding 13 designs were synthesized, and the designed recombinant proteins were expressed in *E. coli* in the presence and absence of the Bpy-Ala. Because Bpy-Ala incorporation is specified with the Amber stop codon, translation of the full-length protein should only occur in the presence of the UAA.


Five of the designed proteins yielded soluble, full-length protein in the presence of Bpy-Ala, with little or no full-length protein observed in its absence (SI Figure 2 and Table 1), suggesting that expression of the proteins was dependent on the presence of Bpy-Ala.

Complexes of bipyridine exhibit  $\pi$ – $\pi^*$  transitions and metal–ligand charge-transfer (MLCT), both of which give rise to spectroscopic signatures in the UV or visible ranges.<sup>16,17</sup> Immediately after purification, the proteins were subjected to spectroscopic analysis in the range of 230–700 nm to probe  $\pi$ – $\pi^*$  (240 and 310 nm) or MLCT electronic transitions. MLCT wavelengths depend on the identity of the bound metal but generally fall within the visible range.<sup>16,17</sup> Of the five proteins examined, two (CB\_02 and CB\_12) were observed to have a spectroscopic signature in a wavelength range indicative of a complex formed from Bpy-Ala and  $\text{Fe}^{2+}$  (Figure 1a and SI Figure 3).

The crystal structure of CB\_02, a design based on the scaffold with PDB ID 1eus, was solved to 1.4 Å resolution (Figure 1b). Unexpectedly, the loop on which the Bpy-Ala UAA resides was flipped out into solvent, and no electron density corresponding to either Bpy-Ala or the bound metal was observed. The presence of Bpy-Ala in CB\_02 was confirmed by mass spectrometric analysis (SI Figure 4). Bpy forms very stable homotrimeric complexes with a number of divalent cations including  $\text{Ni}^{2+}$ ,  $\text{Co}^{2+}$ ,  $\text{Fe}^{2+}$ , and  $\text{Zn}^{2+}$ , and the spectroscopic data observed for CB\_02 (Figure 1a) are consistent with the formation of a  $[\text{Fe}(\text{Bpy})_3]^{2+}$  complex (Figure 1a and SI Figure 3). It is likely that the protein-bound Bpy-Ala forms a very stable  $[\text{Fe}(\text{Bpy-Ala}_f)_2(\text{Bpy-Ala}_p)]^{2+}$  complex where (Bpy-Ala<sub>f</sub>) is free Bpy-Ala in the cell and (Bpy-Ala<sub>p</sub>) is Bpy-Ala that has been incorporated in the protein. Such a complex cannot be sterically accommodated by the scaffold, resulting in its inclusion into solvent. Design CB\_12 showed a similar spectroscopic signal to that observed for CB\_02 (Figure 1a) and may also form a solvent exposed  $[\text{Fe}(\text{Bpy-Ala}_f)_2(\text{Bpy-Ala}_p)]^{2+}$  complex.

The crystallographic information obtained for CB\_02 suggested that Bpy-based design efforts should utilize negative design<sup>18</sup>—attempting to disfavor alternative, nonproductive structures—to ensure that the Bpy-Ala remains constrained within the protein scaffold. With this in mind, a second round of computational design was undertaken.

**Second-Round Design Calculations.** Since the first round design results suggested that constraining the Bpy-Ala conformation was critical, we decided to focus primarily on control of metal binding site geometry in second round calculations. In order to simplify other aspects of the design problem, dopamine was replaced with two explicitly modeled water molecules. To better constrain the Bpy-Ala side chain within the protein, it was incorporated into elements of stable secondary structure during the RosettaMatch calculations. To increase the geometric agreement between the best matches and the theozymes, we included Asp and Glu as liganding residues in addition to His. This resulted in an increased number of matches, and hence the best matches have geometries closer to ideal. In order to favor binding of divalent cations that interact with Bpy in octahedral geometries, Tyr was eliminated, as this residue is often observed in trivalent cation binding sites. The Asp and Glu residues were placed so as to make hydrogen bonds to the bound water ligands. As described below, to further favor recapitulation of the sites as designed, we required that the metal binding histidine and bound water molecules form at least one hydrogen bond to the remainder of the protein; the Asp and Glu already make two interactions in the theozymes one to the metal and one to the water ligands. An example of a theozyme is shown in Figure 2.




**Figure 2.** An example theozyme for second-round design calculations. When Asp or Glu was included as a ligand of the bound metal (gray sphere), a hydrogen bond between a metal-bound water and a liganding acidic residue was specified as shown during the calculations. Additional interactions considered during design (hydrogen bonds to bound water molecules and metal-bound histidines and shape complementarity to Bpy-Ala) are shown as semicircles.

In all, 15 octahedral coordination geometries were generated (SI Figure 5) such that the bound water molecules were in axial–axial, mixed axial–equatorial, and equatorial–equatorial orientations and contained Bpy-Ala and Asp, Glu, or His residues in the remaining four coordination sites. RosettaMatch was used to identify placements of the theozymes in native protein scaffolds, with the requirement that Bpy-Ala be placed on an element of secondary structure. The elimination of the requirement that the bulk of an exogenous ligand be accommodated in the designed proteins resulted in a greater number of initial matches than previously observed. For each of the theozyme placements, RosettaDesign was used to optimize the amino acid identities in the second shell to hold the metal binding residues in place via hydrogen bonds and packing interactions. For each design, unrestricted side chain repacking calculations were carried out, and designs in which the metal binding site geometry was completely preserved and each water and histidine ligand made at least one hydrogen bond were selected. To reduce possible problems in folding, designed residues beyond the first shell (directly interacting with the metal) and second shell (interacting with first shell residues) were reverted to their native identities, and genes encoding 28

designs were synthesized. The numbers of matches and designs that satisfied the aforementioned criteria are listed in SI Figure 6.

Of the 28 designs, 9 expressed solubly in *E. coli* only when Bpy-Ala was included in the expression medium, and 2 showed expression in both the presence and absence of Bpy-Ala (SI Figure 7). The 9 purified proteins showing clear Bpy-Ala dependent expression were subjected to spectroscopic analysis in the range of 230–650 nm. Four of the proteins tested exhibited a shoulder on the tryptophan  $A_{280}$  peak from ~290–330 nm consistent with the  $\pi-\pi^*$  transitions of Bpy-Ala metal complexes (Figure 3a), and only one protein showed signal in




**Figure 3.** Spectroscopic analysis of metal binding designs. (a) Absorbance spectra of round 2 designs MB\_02, MB\_06, MB\_07, and MB\_19. The presence of a shoulder in the range of 290–330 nm suggests the presence of Bpy-bound metal ions. The absence of spectroscopic signal in the range of 450–600 nm (enlarged in the inset) suggests that  $[\text{Fe}(\text{Bpy-Ala})_2(\text{Bpy-Ala}_p)]^{2+}$  complexes are not formed. (b) Absorbance spectra of MB\_07 bound to  $\text{Zn}^{2+}$ ,  $\text{Ni}^{2+}$  and  $\text{Co}^{2+}$ . All spectra have features in the 290–330 nm range indicative of Bpy-Ala mediated metal binding. Spectra are normalized to an  $A_{280}$  of 1.0.

the range of 450–600 nm where  $[\text{Fe}(\text{Bpy})_3]^{2+}$  complexes absorb (SI Figure 8a). Thus the Bpy-Ala residues in all but one of the second-round designs that expressed appear to be sufficiently buried that formation of the  $[\text{Fe}(\text{Bpy-Ala})_2(\text{Bpy-Ala}_p)]^{2+}$  complex is disfavored.

The design with the most pronounced absorbance in the range of 290–330 nm, MB\_07 (Figure 3a) utilizes Bpy-Ala, Asp, Glu, and two bound waters as metal ligands. Of the remaining designs with signal in the range of 290–330 nm, only MB\_02 utilized His as one of the metal ligands. Hence, MB\_02 and MB\_07 were subjected to crystallographic analysis.

**Crystal Structures of MB\_07 Bound to  $\text{Co}^{2+}$  and  $\text{Ni}^{2+}$ .** The structure of design MB\_07 (based on PDB lig) was solved to 2.3 Å resolution. The overall topology of the starting



**Figure 4.** X-ray crystallographic analysis of MB\_07 bound to  $\text{Co}^{2+}$  and  $\text{Ni}^{2+}$ . Electron density from a  $2F_o - F_c$  map in the vicinity of the Bpy-Ala bound to  $\text{Co}^{2+}$  (a) and  $\text{Ni}^{2+}$  (c) contoured at  $1.0 \sigma$ . Density for Bpy-Ala,  $\text{Co}^{2+}$  or  $\text{Ni}^{2+}$  (pink and green spheres, respectively), and a metal-bound water molecule (red spheres) is visible. Comparisons of the MB\_07 design model (gray) with the solved crystal structures of MB\_07 bound to  $\text{Co}^{2+}$  (b) and  $\text{Ni}^{2+}$  (d) are shown in pink and green, respectively. In all cases, bound metals are shown in large spheres, and bound waters are shown as small spheres. Dashed lines represent polar interactions observed in the crystal structures that are involved in metal coordination.

scaffold was maintained in the solved structure (backbone rmsd = 0.80 Å). In the designed metal binding site, electron density corresponding to Bpy-Ala, a bound metal ion, and a single water molecule was clearly observed (Figure 4a). As in the design model, the metal ion was coordinated by E159, D184, and Bpy-Ala. While both acidic residues make monodentate interactions with the metal in the design model, E159 coordinates the metal in a bidentate fashion and thus displaces one of the metal-bound waters in the design (Figure 4a,b). The single metal-bound water forms a hydrogen bond with residue S180, an interaction that was explicitly defined in the design. The all-atom rmsd of all residues within 6 Å of the bound metal was only 0.90 Å (Figure 4b). Although Bpy-Ala was modeled as being completely planar, a slight deviation from planarity was observed in the solved structure (Figure 4a,b).

X-ray fluorescence analysis was carried out at the Advanced Light Source (Lawrence Berkeley National Laboratory), and the identity of the bound metal was determined to be  $\text{Co}^{2+}$  (SI


Figure 9a). This is likely due to initial purification of the designs on TALON resin (Clontech, Mountain View, CA), which is an immobilized metal affinity purification resin that contains  $\text{Co}^{2+}$ ; bipyridine forms octahedral complexes with  $\text{Co}^{2+}$ .<sup>19</sup> To determine if MB\_07 has affinity for other metals that interact with bipyridine in an octahedral fashion, purifications of MB\_07 on affinity resins loaded with  $\text{Ni}^{2+}$  and  $\text{Zn}^{2+}$  were carried out. MB\_07 purified on both  $\text{Ni}^{2+}$  and  $\text{Zn}^{2+}$  had similar but not identical absorbance spectra to that after purification on  $\text{Co}^{2+}$  resin (Figure 3b). To examine whether the binding site geometry depends on the bound metal, the  $\text{Ni}^{2+}$  and  $\text{Zn}^{2+}$  loaded proteins were also subjected to crystallographic analysis. The structure of  $\text{Ni}^{2+}$ -bound MB\_07 was solved to 2.5 Å resolution, and the presence of  $\text{Ni}^{2+}$  in the protein was again confirmed with X-ray fluorescence (SI Figure 9b). Overall, the binding mode was identical to that observed in the  $\text{Co}^{2+}$  loaded protein (Figure 4c,d) except that Bpy-Ala in the  $\text{Ni}^{2+}$ -bound protein appeared to deviate less from planarity relative to the

Co<sup>2+</sup> bound structure. The all atom rmsd of residues within 6 Å of the bound metal was 1.0 Å in the Ni<sup>2+</sup> bound structure. Difference density corresponding to a water molecule was observed in the Ni<sup>2+</sup>-bound structure at the same position as in the Co<sup>2+</sup> structure in an  $F_o - F_c$  map (calculated after a round of refinement in REFMAC in the absence of modeled water) (SI Figure 10), suggesting a metal-bound water molecule is present in the Ni<sup>2+</sup> structure as well. MB\_07 also binds Fe<sup>2+</sup> (SI Figure 11), but we were unable to solve the structure of that complex.

**Metal Binding Affinity of MB\_07.** To determine the affinity of MB\_07 for metal, we first titrated Zn<sup>2+</sup> into apo MB\_07 (see SI Methods) and monitored the change in absorbance at 310 nm (SI Figure 12a). The absorbance increased linearly until the metal and protein concentrations were equal, at which point no further increase in signal was observed. A nonlinear least-squares fit of these data suggested an upper limit of the  $K_d$  of 10 nM (SI Figure 12a,b and SI methods).

To increase sensitivity at low Zn<sup>2+</sup> concentrations, we used the Zn<sup>2+</sup>-sensitive chromophore 4-(2-pyridylazo)resorcinol (PAR), which binds Zn with a  $K_d$  of 250 nM.<sup>20</sup> Removal of Zn from PAR was monitored through the change in absorbance at 500 nm as apo MB\_07 was titrated into a solution of PAR and Zn<sup>2+</sup>. As the concentration of apo MB\_07 was increased, a linear decrease in absorbance at 500 nm was observed until the protein and metal concentrations were equal, at which point the  $A_{500}$  was indistinguishable from apo PAR (SI Figure 12c). Fits of these data suggest the  $K_d$  of MB\_07 for Zn<sup>2+</sup> is <1 nM (SI Figure 12c,d).

To probe still lower Zn<sup>2+</sup> concentrations, the Zn<sup>2+</sup> sensitive fluorescent probe FluoZin-3 (Life Technologies), with a  $K_d$  for Zn<sup>2+</sup> of 15 nM,<sup>21</sup> was used to carry out a competition assay similar to that described with PAR. A fit of the fluorescence intensity as a function of protein concentration yielded an estimate of the  $K_d$  of MB\_07 for Zn<sup>2+</sup> of  $37 \pm 15$  pM (Figure 5 and SI Figure 14). Because the  $K_d$  value obtained from the fits is far lower than the  $K_d$  of FluoZin-3 for Zn<sup>2+</sup>, it was difficult to



**Figure 5.** Determination of MB\_07 binding affinity. Normalized fluorescence values, proportionate to the concentration of FluoZin-3 bound to Zn<sup>2+</sup>, are shown for ZnSO<sub>4</sub> and FluoZin-3 in the presence of apo MB\_07 ranging in concentration from 2 nM to 1 μM (see SI). Simulated fits were generated using eqs 12–15 in the SI and are shown for  $K_d$  values ranging from 1 pM to 1 nM. The curve of best fit, corresponding to a  $K_d$  of 36.8 pM is shown in black.

measure this value precisely, and 37 pM is likely an upper bound.

## DISCUSSION

The combination of genetically encoded UAAs with computational protein design methods allows control over both the placement of the UAA within a protein and the interactions between the UAA and the surrounding protein environment. One reason that metalloprotein design has been difficult is that the precise orientations of multiple protein side chains must be explicitly defined. Bpy-Ala has advantages for metal binding site design. First, the two pyridine nitrogens are pre-positioned in an orientation compatible with metal binding (the entropic cost of which is paid during the synthesis of the side chain itself). In contrast, design of a metal binding site using imidazole nitrogens from two histidine residues requires precise control over the relative orientation of the two side chains. Second, Bpy-Ala is uncharged, and can therefore be utilized in the design of quite buried sites. As observed in the structure of MB\_07, the orientation of Bpy-Ala can be buttressed through hydrophobic packing interactions, which is not the case in metal binding sites constructed from polar residues, which must be stabilized through extensive hydrogen-bonding networks.

Our initial designs with Bpy-Ala on portions of the protein not well constrained by the remainder of the scaffold resulted in the extrusion of Bpy-Ala to solvent, likely due to the formation of a  $[\text{Fe}(\text{Bpy-Ala}_r)_2(\text{Bpy-Ala}_p)]^{2+}$  complex. Modifications to the initial design protocol were implemented to address this problem, and a second round of design was carried out. Of nine Bpy-Ala containing second round designs that expressed solubly, only one exhibited a spectroscopic signal indicative of formation of a  $[\text{Fe}(\text{Bpy-Ala}_r)_2(\text{Bpy-Ala}_p)]^{2+}$  complex (SI Figure 8a). Structural analysis of the second round design MB\_07, confirmed the formation of an octahedral metal binding site as designed. Not only is Bpy-Ala relatively buried in this design, it is sandwiched between leucine and phenylalanine residues from the native scaffold. These data suggest that metal binding UAA cofactors should be well constrained within a protein scaffold to realize the desired functional site geometry.

Competition experiments suggest the affinity of MB\_07 for Zn<sup>2+</sup> is ~40 pM. The  $K_d$  of Bpy for Zn<sup>2+</sup> is reported to be 7.5 μM,<sup>19</sup> hence the additional designed residues contribute substantially to affinity.

MB\_07 was designed to have metal binding ability but not enzymatic activity. In certain metalloenzymes (e.g., zinc hydrolases), bound metal ions act as Lewis acids that serve to activate substrates for nucleophilic attack.<sup>22</sup> Moreover, a metal-bound water molecule, itself activated by the metal, often serves as the active site nucleophile in such cases.<sup>22</sup> While a close match was observed between the designed metal binding site and the solved structure, higher accuracy in the coordination geometry would be required for success with a designed metalloenzyme. Nonetheless, this designed metal binding site could provide the starting point for the subsequent design of UAA dependent hydrolases. More generally, the methods developed and insights gained in this study should be directly useful for designing a wide range of UAA-based functional sites.

## CONCLUSION

We report the extension of computational protein design methods to generate a protein with the ability to bind metals with high affinity by exploiting the inherent chemical

functionality of a genetically encoded unnatural amino acid. Structural characterization revealed the importance of controlling the conformation of the introduced unnatural amino acid. The methods and insights from this work will inform the design of unnatural amino acid-based enzyme catalysts.

## METHODS

**Protein Expression, Purification, and Analysis.** Designed proteins were ordered from Genscript in a pET29b expression plasmid (EMD Millipore) and contained an Amber stop codon at the desired position of Bpy-Ala incorporation. Protein expression was carried out in the *E. coli* BL21(DE3) cell line. BL21(DE3) cells were cotransformed with each design in pET29b and pEVOL-BpyRS (Schultz Laboratory, The Scripps Research Institute).<sup>23</sup> The pEVOL-BpyRS plasmid contains an orthogonal tRNA with an anticodon loop specific to the Amber stop codon, and an aminoacyl tRNA synthetase evolved to acylate the orthogonal tRNA with Bpy-Ala. Protein expression was carried out in Terrific Broth at 18 °C in the presence of 500  $\mu$ M *rac*-Bpy-Ala. Protein purification was carried out using TALON resin (Clontech), Ni-NTA resin (Qiagen), or Zn<sup>2+</sup> loaded Hi-trap chelating resin (G.E. Biosciences). Protein purity and size were analyzed using SDS-PAGE analysis. All absorbance spectra were collected on a Molecular Devices Spectramax M5<sup>e</sup> microplate reader.

**CB\_02 Structure Determination.** CB\_02 was purified on TALON resin, followed by anion exchange chromatography and gel filtration. Purified protein was concentrated to 5 mg/mL in 10 mM Tris buffer, pH 8.0. Crystals were grown using the microbatch method at 21 °C and a precipitant solution of 100 mM sodium cacodylate (pH 6.5) and 15% (w/v) PEG 3350. Solutions were supplemented with 5 mM FeCl<sub>2</sub>, and crystals were grown in a COY anaerobic glovebox with O<sub>2</sub> levels maintained below 2 ppm to prevent oxidation of the iron. Crystals were flash frozen in liquid nitrogen after immersion in precipitant solution supplemented with 25% (v/v) glycerol, and data were collected at 100 K. A native diffraction data set to resolution 1.4 Å was collected on a single crystal of CB\_02 at the X4C beamline of the National Synchrotron Light Source (NSLS). The diffraction images were processed with the HKL package.<sup>24</sup> The data processing statistics are summarized in SI Table 3. The structure was determined by the molecular replacement method with the program COMO,<sup>25</sup> using the structure of the bacterial sialidase (PDB id: 1euu) as the search model. The complete atomic model was built with the program XtalView<sup>26</sup> and refined with the program CNS<sup>27</sup> and Phenix.<sup>28</sup> Since the side chain of the Bpy-Ala at position 92 is disordered in the structure, it was modeled as an alanine residue. The *C $\alpha$*  rmsd between the design and solved structure was calculated to be 1.07 Å. The structure of CB\_02 represents target OR61 of the North East Structural Genomics consortium.

**MB\_07 Structure Determination.** Cobalt-bound MB\_07 was purified on TALON resin followed by anion exchange and gel filtration. Purified protein was concentrated to 10 mg/mL in 10 mM Tris pH 7.6, with 50 mM NaCl. Crystals of cobalt-bound MB\_07 grew in 1.8 M ammonium sulfate, 5% PEG 3350, and 50 mM BisTris pH 6.5. Nickel-bound MB\_07 was first purified on Ni-NTA resin (Qiagen), followed by anion exchange and gel filtration. Purified protein was again concentrated to 10 mg/mL in the buffer described above. Crystals grew in 1.6 M ammonium sulfate supplemented with 3% PEG 3350 and 50 mM BisTris at pH 6.5. In both cases, crystals were flash cooled after soaking in two stages of glucose cryoprotectant. Data were collected on an RaxisIV++. HKL2000<sup>24</sup> was used to process and scale the data to 2.3 Å resolution for the MB\_07-Co structure and 2.5 Å for the MB\_07-Ni structure. CCP4<sup>29</sup> was used to determine phases by molecular replacement, using the structure with PDB ID 1igs with truncated design residues as a search model. Coot<sup>30</sup> and Refmac<sup>31</sup> were used for model building and refinement, respectively, excluding a random 5% of the data for cross validation. Statistics are shown in SI Table 4. Identities of the Bipy-bound metals were confirmed via X-ray fluorescence data collected at beamline 5.0.2 at the ALS (Advanced Light Source, Lawrence Berkeley Laboratory, Berkeley, CA).

Unbiased density was observed for the unnatural amino acid Bpy-Ala with bound metal, which was the strongest feature in density, at 7.8  $\sigma$  in the case of cobalt and 8.6  $\sigma$  for nickel. Co-bound MB\_07 showed a *C $\alpha$*  rmsd from the design structure of 0.79 Å, while Ni-bound MB\_07 had a *C $\alpha$*  rmsd 0.49 Å.

**Identification of Bound Metals.** X-ray fluorescence data were collected at the Advanced Light Source (ALS) synchrotron facility at the Lawrence Berkeley National Laboratory (University of California) on beamline 5.0.2 with the assistance of ALS staff. Metal edges of Cu, Ni, Co, Fe, Zn, and Mg were scanned using in house BOS software. Metal edge fluorescence data are shown in SI Figure 9.

**Determination of the *K<sub>d</sub>* of MB\_07 for Zn<sup>2+</sup>.** A competition assay was carried out in which MB\_07 was titrated into a mixture of FluoZin-3 and ZnSO<sub>4</sub>. The FluoZin-3 and ZnSO<sub>4</sub> concentrations were 1  $\mu$ M and 100 nM, respectively, and apo MB\_07 was present at concentrations ranging from 2 nM to 1  $\mu$ M (see SI Methods). All data were collected on a SpectraMax M5<sup>e</sup> microplate reader in cuvette mode. Nonlinear least-squares fitting of the data was carried out using Origin 7.0 software.

## ASSOCIATED CONTENT

### Supporting Information

Example theozymes, protein expression and characterization data, and detailed methods of computational design, protein expression, and *K<sub>d</sub>* determinations. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## AUTHOR INFORMATION

### Corresponding Author

dabaker@u.washington.edu

### Present Address

<sup>#</sup>Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, New Jersey, United States.

### Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

The authors thank Peter Schultz for the generous gift of the pEVOL-BpyRS plasmid, and Lubica Supekova for assistance in transferring the plasmid to us. We thank Christine Tinberg, Neil King, and Yifan Song for helpful discussions. We thank Randy Abramowitz and John Schwanof for setting up the X4C beamline, and Gaetano Montelione and Greg Kornhaber for assistance in facilitating the crystallographic analysis of CB\_02. This research was supported by the Defense Advanced Research Projects Agency (HR001-08-0085 ARPA) and the Defense Threat Reduction Agency (HDTRA1-11-1-0041). Research reported in this publication was supported by NIGMS of the National Institutes of Health under award no. F32GM099210 to J.H.M. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. The structures of CB\_02 and MB\_07 bound to Co and Ni have been deposited in the RCSB Protein Databank under accession codes 4j9t, 4iww, and 4ix0, respectively.

## REFERENCES

- (1) Liu, C. C.; Schultz, P. G. *Annu. Rev. Biochem.* **2010**, *79*, 413.
- (2) Wang, J.; Xie, J.; Schultz, P. G. *J. Am. Chem. Soc.* **2006**, *128*, 8738.
- (3) Lippard, S. J.; Berg, J. M. *Principles of Bioinorganic Chemistry*; University Science Books: Mill Valley, 1994.
- (4) Lu, Y.; Yeung, N.; Sieracki, N.; Marshall, N. M. *Nature* **2009**, *460*, 855.
- (5) Lu, Y. *Curr. Opin. Chem. Biol.* **2005**, *9*, 118.

- (6) DeGrado, W. F.; Summa, C. M.; Pavone, V.; Nastro, F.; Lombardi, A. *Annu. Rev. Biochem.* **1999**, *68*, 779.
- (7) Hellinga, H. W. *Fold. Des.* **1998**, *3*, R1.
- (8) Iverson, B. L.; Iverson, S. A.; Roberts, V. A.; Getzoff, E. D.; Tainer, J. A.; Benkovic, S. J.; Lerner, R. A. *Science* **1990**, *249*, 659.
- (9) Telmer, P. G.; Shilton, B. H. *J. Mol. Biol.* **2005**, *354*, 829.
- (10) Der, B. S.; Machius, M.; Miley, M. J.; Mills, J. L.; Szyperki, T.; Kuhlman, B. *J. Am. Chem. Soc.* **2012**, *134*, 375.
- (11) Salgado, E. N.; Faraone-Mennella, J.; Tezcan, F. A. *J. Am. Chem. Soc.* **2007**, *129*, 13374.
- (12) Xie, J.; Liu, W.; Schultz, P. G. *Angew. Chem., Int. Ed. Engl.* **2007**, *46*, 9239.
- (13) Lee, H. S.; Spraggon, G.; Schultz, P. G.; Wang, F. *J. Am. Chem. Soc.* **2007**, *131*, 2481.
- (14) Zanghellini, A.; Jiang, L.; Wollacot, A. M.; Cheng, G.; Meiler, J.; Althoff, E. A.; Röthlisberger, D.; Baker, D. *Protein Sci.* **2006**, *15*, 2785.
- (15) Kuhlman, B.; Baker, D. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 10383.
- (16) Meyer, T. J. *Pure Appl. Chem.* **1986**, *58*, 1193.
- (17) Mason, S. F. *Inorg. Chim. Acta. Rev.* **1968**, *2*, 89.
- (18) Hect, M. H.; Richardson, J. S.; Richardson, D. C.; Ogden, R. C. *Science* **1990**, *249*, 884.
- (19) Smith, R. M.; Martell, A. E. *Critical Stability Constants; Amines*; Plenum Press: New York, 1975; Vol 2, pp 235–236.
- (20) Hunt, J. B.; Neece, S. H.; Ginsburg, A. *Anal. Biochem.* **1985**, *146*, 150.
- (21) Gee, K. R.; Zhou, Z. L.; Qian, W. J.; Kennedy, R. *J. Am. Chem. Soc.* **2002**, *124*, 776.
- (22) Matthews, B. W. *Acc. Chem. Res.* **1998**, *21*, 333.
- (23) Young, T. S.; Ahmad, I.; Yin, J. A.; Schultz, P. G. *J. Mol. Biol.* **2010**, *395*, 367.
- (24) Otwinowski, Z.; Minor, W. *Method. Enzymol.* **1997**, *276*, 307.
- (25) Jogle, G.; Tao, X.; Xu, Y.; Tong, L. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2001**, *57*, 1127.
- (26) McRee, D. E. *J. Struct. Biol.* **1999**, *125*, 156.
- (27) Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **1998**, *54*, 905.
- (28) Adams, P. D.; Afonine, P. V.; Bunkóczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2010**, *66*, 213.
- (29) Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; Keegan, R. M.; Krissinel, E. B.; Leslie, A. G. W.; McCoy, A.; McNicholas, G. N.; Murshudov, G. N.; Pannu, N. S.; Pottterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2011**, *67*, 235.
- (30) Emsley, P.; Cowtan, K. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2004**, *60*, 2126.
- (31) Vagin, A. A.; Steiner, R. S.; Lebedev, A. A.; Pottterton, L.; McNicholas, S.; Long, F.; Murshudov, G. N. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2004**, *60*, 2284.